

## References and Author Notes: Chapter 12

- Dtsch. Arztebl. Int.*, 2014;111:493–502, 433 p following 502.  
DOI: 10.3238/arztebl.2014.0493.
9. H. Matthes, et al. “Supportive care in pancreatic carcinoma patients treated with a fermented mistletoe (*Viscum album* L.) extracts,” in R. Scheer, et al (eds.), *Die Mistel in der Tumorthherapie 2, Akuteller Stand der Forschung und klinische Anwendung*. Essen: KVC Verlag; 2008.
  10. AUTHOR NOTE: Trial is registered at <https://clinicaltrials.gov/ct2/show/NCT03051477>. Updates on study publications will be available at <http://mistletoebook.com>.
  11. T. Ostermann, et al. “A systematic review and meta-analysis on the survival of cancer patients treated with a fermented *Viscum album* L. extract (Iscador®): An update of findings,” *Complementary Med. Res.*, 2020, DOI: 10.1159/000505202.
  12. M. Loef and H. Walach. “Quality of life in cancer patients treated with mistletoe: A systematic review and meta-analysis,” Op. cit.

## CHAPTER 12

1. AUTHOR NOTE: According to data at Steiner Health, “By some estimates, 40 percent of French, and up to 60 percent of German cancer patients receive this botanical extract” (<https://steinerhealth.org/articles/alternative-cancer-treatment/>. Retrieved Apr. 29, 2021).
2. Trial details and registration at <https://clinicaltrials.gov/ct2/show/NCT03051477>.
3. M. E. Porter and T. H. Lee. “The strategy that will fix health care,” *Harvard Business Review* (Oct. 2013); <https://hbr.org/2013/10/the-strategy-that-will-fix-health-care> Accessed Apr. 22, 2021.
4. M. E. Porter and E. Olmsted Teisberg. “Redefining health care: Creating value-based competition on results,” *Harvard Business Review*, 2006.
5. A. Ladanie, et al. “Clinical trial evidence supporting US Food and Drug Administration approval of novel cancer therapies between 2000 and 2016,” *JAMA Network Open*, 2020;3(11):e2024406. doi:10.1001/jamanetworkopen.2020.24406.
6. Hyeonjun Yun, et al. “Growth of integrative medicine at leading cancer centers between 2009 and 2016: A systematic analysis of NCI-designated comprehensive cancer center websites,” *JNCI Monographs*, vol. 2017, no. 52, Nov. 2017, lgx004, <https://doi.org/10.1093/jncimonographs/lgx004>.
7. S. J. Grant, et al. “Integrative oncology: International perspectives,” *Integrative Cancer Therapies*, vol. 18 (2019): 1534735418823266. doi:10.1177/1534735418823266.
8. C. A. Buckner, et al. “Complementary and alternative medicine use in patients before and after a cancer diagnosis,” *Current Oncology* (Toronto), vol. 25,4 (2018): e275–e281. doi:10.3747/co.25.3884.
9. Trial details and registration at <https://clinicaltrials.gov/ct2/show/NCT03051477>.
10. Per data published by Mistletoe-Therapy.org: “Currently 154 studies have been conducted on the anthroposophical mistletoe preparations